The Medicines Company

The Medicines Company is a pharmaceutical firm dedicated to improving the treatment of critical care patients by offering innovative and cost-effective medicines to hospitals worldwide. The company's primary product, Angiomax, is an anticoagulant used in conjunction with aspirin for patients undergoing coronary angioplasty. Additionally, The Medicines Company markets Cleviprex, an injectable emulsion for managing blood pressure when oral medications are not suitable. In its development pipeline, the company has two late-stage products: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. Furthermore, The Medicines Company is exploring a serine protease inhibitor, CU2010, which is currently in early-stage development.

Victoria Kusiak MD

Senior Vice President

8 past transactions

Annovation BioPharma

Acquisition in 2015
Annovation BioPharma develops pharmaceutical products in the field of anesthesia, sedation, and sleep. The company was incorporated in 2009 and is based in Wayland, Massachusetts.

Tenaxis Medical

Acquisition in 2014
Tenaxis Medical, Inc. is a company established in 2004 that specializes in the development and commercialization of high-performance sealants and anti-adhesion agents. These products are designed for applications in vascular and general surgery, aimed at improving patient outcomes by reducing complications associated with surgical procedures. Through its innovative approach, Tenaxis Medical addresses critical needs within the surgical market, enhancing the effectiveness and safety of surgical interventions.

Rempex Pharmaceuticals

Acquisition in 2013
Rempex Pharmaceuticals, Inc. is a San Diego-based pharmaceutical company dedicated to the discovery and development of innovative antibacterial drugs aimed at addressing the urgent clinical challenges posed by multi-drug resistant bacterial pathogens. The company focuses on an internal development pipeline that integrates proprietary formulations and novel potentiating agents with established antibiotics. This approach is designed to overcome or directly inhibit the molecular mechanisms that contribute to antibiotic resistance, thereby enhancing the efficacy of existing treatments and improving patient outcomes.

ProFibrix

Acquisition in 2013
ProFibrix B.V. is a biotechnology company focused on developing and marketing innovative products for the hemostasis and regenerative medicine sectors. Founded in 2004, the company specializes in Fibrocaps, a dry powder topical hemostat and tissue sealant designed to effectively control acute and severe bleeding during surgical procedures or due to traumatic injuries. Fibrocaps is formulated from a blend of fibrinogen and thrombin, two key proteins vital for blood clotting and tissue repair. Additionally, ProFibrix offers a sterilized single-use delivery device that facilitates the application of Fibrocaps to targeted areas, minimizing the need to manipulate the wound in a surgical setting. The company's products leverage human fibrinogen, a natural blood protein, to enhance hemostatic efficacy and promote healing.

Incline Therapeutics

Acquisition in 2012
Incline Therapeutics is a privately-held specialty pharmaceutical company that concentrates on developing innovative pain management solutions for hospital settings. The company's primary focus is on IONSYS, a fentanyl iontophoretic transdermal system designed as a patient-controlled analgesia option for adult inpatients who require opioid pain relief following surgery. This system offers a compact and disposable approach, utilizing a needleless design for the short-term management of postoperative pain. Incline Therapeutics is backed by prominent life science venture capital firms and is guided by an experienced management team with considerable expertise in the pharmaceutical and medical device industries.

ApoA-I Milano

Acquisition in 2009
ApoA-I Milano is a company that was acquired by The Medicines Company in 2009.

Curacyte Discovery GmbH

Acquisition in 2008
Curacyte Discovery GmbH is a biopharmaceutical company which develops selective inhibitors of urokinase-type plasminogen activator.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.